Angiotensin‑converting enzyme inhibitors are first‑line antihypertensives recommended by ACC/AHA and ESC guidelines. This comprehensive guide explains how they work, who benefits most, common agents, side effects, and how to use them safely with lifestyle measures.
- What Are ACE Inhibitors and How Do They Lower Blood Pressure?
- Who Should Take ACE Inhibitors? — Key Indications and Patient Profiles
- ACE Inhibitors vs. Other Antihypertensives: A Practical Comparison
- Common ACE Inhibitors and Typical Dosing
- Side Effects, Contraindications, and Monitoring
- Important Drug Interactions
- Lifestyle and Monitoring While on ACE Inhibitors
- Frequently Asked Questions About ACE Inhibitors
- Common Myths and Misconceptions
- When to Call Your Doctor — Red Flags
What Are ACE Inhibitors and How Do They Lower Blood Pressure?
Angiotensin‑converting enzyme (ACE) inhibitors block the enzyme that converts angiotensin I to angiotensin II, a potent vasoconstrictor. By reducing angiotensin II levels, they promote vasodilation, decrease aldosterone secretion, and lower peripheral vascular resistance. This leads to a sustained reduction in both systolic and diastolic blood pressure.
The renin‑angiotensin‑aldosterone system (RAAS) plays a central role in blood pressure regulation. ACE inhibitors interrupt this cascade, leading to lower angiotensin II levels, reduced aldosterone, decreased sodium and water retention, and vasodilation. Unlike angiotensin receptor blockers (ARBs), ACE inhibitors also increase bradykinin, which contributes to vasodilation but also explains the common side effect of dry cough.
“In patients with hypertension and comorbidities such as heart failure, diabetes, or chronic kidney disease, ACE inhibitors reduce mortality and delay progression of nephropathy.”
— 2022 AHA/ACC/HFSA Heart Failure Guideline, §5.2
Beyond blood pressure reduction, ACE inhibitors provide target‑organ protection. Landmark trials like HOPE (ramipril) and ALLHAT (lisinopril) demonstrated significant reductions in cardiovascular death, myocardial infarction, and stroke, independent of BP lowering. They are particularly beneficial in patients with left ventricular systolic dysfunction, diabetic nephropathy, and stable coronary artery disease.
Who Should Take ACE Inhibitors? — Key Indications and Patient Profiles
ACE inhibitors are recommended as first‑line therapy for non‑Black patients with hypertension, especially when comorbid conditions are present. For Black patients, the 2017 ACC/AHA guideline notes that ACE inhibitors may be less effective as monotherapy; thiazide diuretics or calcium channel blockers are preferred initially. However, combination therapy can still include an ACE inhibitor.
- Hypertension (stage 1 or 2, systolic ≥130 mmHg or diastolic ≥80 mmHg)
- Heart failure with reduced ejection fraction (HFrEF)
- Diabetic nephropathy (albuminuria >30 mg/g)
- Chronic kidney disease (eGFR <60 mL/min/1.73 m², especially with proteinuria)
- Post‑myocardial infarction to prevent remodeling
- High cardiovascular risk (stable coronary artery disease)
ACE inhibitors are also indicated for patients with metabolic syndrome, since they do not adversely affect glucose metabolism or lipid profiles. In fact, they may improve insulin sensitivity slightly. However, they should not be used in pregnancy (risk of fetal renal abnormalities and oligohydramnios).
Which patient populations derive the most benefit?
The greatest absolute benefit is seen in patients with heart failure, diabetes with albuminuria, and those with a history of myocardial infarction. In the HOPE trial, ramipril reduced the primary composite endpoint (CV death, MI, stroke) by 22% in high‑risk patients with normal ejection fraction. In diabetic patients, ACE inhibitors slow progression of microalbuminuria to overt nephropathy.
ACE Inhibitors vs. Other Antihypertensives: A Practical Comparison
Mechanism: Blocks ACE → ↓ angiotensin II, ↑ bradykinin
Common S/E: Dry cough (5–20%), angioedema (rare), hyperkalemia
Renal protection: Yes (reduces proteinuria)
Metabolic effects: Neutral or mild improvement in insulin sensitivity
Pregnancy safety: Contraindicated (teratogenic)
Mechanism: Blocks AT1 receptor → ↓ angiotensin II effects, no bradykinin
Common S/E: Very low cough rate, hyperkalemia possible
Renal protection: Similar to ACEi
Metabolic effects: Neutral
Pregnancy safety: Contraindicated
Mechanism: ↑ Na/Cl excretion, mild vasodilation
Common S/E: Hypokalemia, hyponatremia, hyperglycemia, ↑ uric acid
Renal protection: Less potent than ACEi for proteinuria
Metabolic effects: May worsen glucose and lipids
Pregnancy safety: Avoid in 2nd/3rd trimester
Mechanism: Blocks L‑type Ca channels → vasodilation
Common S/E: Ankle edema, headache, gingival hyperplasia
Renal protection: Less antiproteinuric effect
Metabolic effects: Neutral
Pregnancy safety: Nifedipine OK; avoid diltiazem/verapamil
In clinical practice, the choice between an ACE inhibitor and an ARB often comes down to tolerability. Both classes confer similar cardiovascular and renal benefits. The ONTARGET trial showed non‑inferiority of telmisartan (ARB) versus ramipril, with fewer cough episodes. Combination of ACEi + ARB is generally discouraged due to increased risk of hyperkalemia and hypotension without added benefit.
Common ACE Inhibitors and Typical Dosing
The most frequently prescribed ACE inhibitors in the U.S. include lisinopril, enalapril, ramipril, and benazepril. All are available as generic, low‑cost formulations. Dosing depends on renal function, age, and volume status. Always start with a low dose and titrate gradually to minimize first‑dose hypotension.
| Drug | Starting Dose | Usual Maintenance | Notes |
|---|---|---|---|
| Lisinopril | 5–10 mg once daily | 20–40 mg once daily | Most commonly prescribed; once‑daily dosing |
| Enalapril | 5 mg once daily | 10–40 mg/day in 1–2 doses | Short half‑life; twice‑daily may be needed |
| Ramipril | 2.5 mg once daily | 10–20 mg/day in 1–2 doses | Proven CV risk reduction in HOPE trial |
| Benazepril | 10 mg once daily | 20–40 mg once daily | Often combined with amlodipine or HCTZ |
| Captopril | 25 mg BID or TID | 25–150 mg/day in 3 divided doses | Short duration; seldom used for hypertension alone |
Check serum creatinine and potassium within 1–2 weeks of starting or adjusting dose. If potassium rises above 5.5 mEq/L or eGFR drops >30%, reduce dose or consider alternative. Do not start if potassium >5.0 mEq/L without careful evaluation.
Side Effects, Contraindications, and Monitoring
ACE inhibitors are generally well‑tolerated, but several side effects require attention. The most common is a dry, persistent cough (5–20% of patients), thought to be due to bradykinin accumulation. If cough is bothersome, switching to an ARB is a reasonable alternative because ARBs do not affect bradykinin.
- Pregnancy: ACE inhibitors cause fetal renal damage, oligohydramnios, and neonatal death. Discontinue immediately if pregnancy is confirmed.
- History of angioedema (even mild) with any ACE inhibitor — do not rechallenge.
- Bilateral renal artery stenosis — can precipitate acute kidney injury.
- Severe hyperkalemia (K+ >5.5 mEq/L) — avoid unless benefit clearly outweighs risk.
- Hypovolemia or sodium depletion — correct volume status before starting.
Less common but serious side effects
Angioedema (swelling of lips, tongue, airways) is a rare but life‑threatening adverse effect. It can occur within hours to days after starting the drug. Immediate discontinuation and emergency medical care are required. Neutropenia and agranulocytosis are extremely rare, more common in patients with collagen vascular disease or high‑dose captopril therapy.
How to monitor safely
Baseline and periodic labs: serum creatinine, eGFR, potassium, and blood pressure. In stable patients with normal renal function, annual monitoring is sufficient. For elderly or CKD patients, recheck within 1–2 weeks of dose changes.
Important Drug Interactions
- Non‑steroidal anti‑inflammatory drugs (NSAIDs): Ibuprofen, naproxen, celecoxib — reduce antihypertensive effect and increase risk of acute kidney injury and hyperkalemia.
- Potassium supplements or potassium‑sparing diuretics (spironolactone, eplerenone, amiloride): Synergistic hyperkalemia risk. Monitor potassium closely.
- Lithium: ACE inhibitors increase lithium levels — toxicity risk. Monitor lithium levels.
- Diuretics (especially high‑dose loop diuretics): Volume depletion can cause first‑dose hypotension.
- Dual RAAS blockade (ACEi + ARB + direct renin inhibitor): No added CV benefit; increased risk of hyperkalemia, hypotension, and AKI.
A common clinical scenario: a patient with hypertension and osteoarthritis takes ibuprofen regularly. The NSAID partially blunts the BP‑lowering effect of the ACE inhibitor and increases sodium retention. Consider acetaminophen or topical NSAIDs instead. If NSAID use is unavoidable, increase antihypertensive dose and monitor BP and renal function every 3 months.
Lifestyle and Monitoring While on ACE Inhibitors
Medication alone is rarely sufficient to achieve long‑term blood pressure targets. The 2025 American Society of Hypertension recommends combining pharmacological therapy with lifestyle measures for optimal cardiovascular risk reduction.
The PREMIER trial showed that combining the DASH diet, sodium restriction, and exercise with antihypertensive medication results in a mean systolic BP reduction of ~16 mmHg, compared to ~6 mmHg with medication alone. ACE inhibitors work synergistically with these lifestyle changes to improve vascular health and reduce inflammation.
Frequently Asked Questions About ACE Inhibitors
Why do ACE inhibitors cause a cough? — Bradykinin connection
ACE is also the enzyme that degrades bradykinin, a pro‑inflammatory peptide. By blocking ACE, bradykinin levels rise, especially in the upper respiratory tract. This stimulates cough receptors. The cough is non‑productive, dry, and may appear weeks to months after starting therapy. Switching to an ARB usually resolves the cough completely.
Can I take ACE inhibitors if I have kidney disease? — Yes, with caution
ACE inhibitors are indicated for chronic kidney disease (CKD) with albuminuria because they reduce proteinuria and slow progression. However, close monitoring of creatinine and potassium is essential. A small, early rise in creatinine (up to 30%) is acceptable and reflects hemodynamic adaptation. If eGFR declines >30% or potassium exceeds 5.5 mEq/L, the dose should be reduced or stopped.
What should I do if I miss a dose? — Simple rule
Take the missed dose as soon as you remember, unless it is almost time for the next dose. In that case, skip the missed dose and resume your regular schedule. Never double up — that can cause a sudden drop in blood pressure.
Are ACE inhibitors safe in older adults? — Yes, but start low and go slow
Older adults are more sensitive to volume depletion and first‑dose hypotension. Start with half the standard dose (e.g., lisinopril 2.5 mg) and titrate every 2–4 weeks. Also monitor renal function and electrolytes regularly. ACE inhibitors remain first‑line in the 2018 ESC/ESH guideline for patients ≥80 years old.
Common Myths and Misconceptions
In fact, ACE inhibitors are renoprotective. They reduce intraglomerular pressure and slow the progression of diabetic and nondiabetic CKD. The small, early increase in serum creatinine (<30%) is normal and not a sign of injury. Only in conditions like bilateral renal artery stenosis or severe volume depletion can they cause harm.
Lifestyle changes alone can sometimes reduce or eliminate the need for medication. Weight loss, the DASH diet, and regular exercise have been shown to normalize blood pressure in some individuals. However, never stop your ACE inhibitor without medical supervision, as rebound hypertension can occur.
ALLHAT found that lisinopril was slightly less effective in preventing stroke in Black participants compared to a thiazide diuretic (chlorthalidone). However, overall CV outcomes were similar. The 2017 ACC/AHA guideline still recommends ACE inhibitors for Black patients when used in combination with a diuretic or calcium channel blocker. Monotherapy in Black patients is less effective due to lower renin levels.
Angioedema occurs in about 0.1–0.7% of users. It can be fatal if it affects the airway. If you develop swelling of the lips, tongue, throat, or face, stop the medication and seek emergency care immediately. Once angioedema has occurred, do not use any ACE inhibitor again, and avoid ARBs in the first few months.
When to Call Your Doctor — Red Flags
Although ACE inhibitors are safe for most people, certain symptoms require immediate medical attention. The following warning signs should not be ignored.
If you experience any of these symptoms, stop the ACE inhibitor (unless otherwise directed) and contact your healthcare provider immediately. Do not wait for a routine appointment.
